Clarifications on the safety of dexrabeprazole vs. omeprazole in the treatment of gastroesophageal reflux disease.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): López-Suárez CM;López-Suárez CM
  • Source:
    Gaceta medica de Mexico [Gac Med Mex] 2023; Vol. 159 (4), pp. 364-365.
  • Publication Type:
    Letter; Comment
  • Language:
    English
  • Additional Information
    • Transliterated Title:
      Precisiones sobre la seguridad de dexrabeprazol versus omeprazol en el tratamiento de la enfermedad por reflujo gastroesofágico.
    • Source:
      Publisher: Unidad de Congresos del Centro Médico Nacional Country of Publication: Mexico NLM ID: 0010333 Publication Model: Print Cited Medium: Internet ISSN: 0016-3813 (Print) Linking ISSN: 00163813 NLM ISO Abbreviation: Gac Med Mex Subsets: MEDLINE
    • Publication Information:
      Original Publication: México : Unidad de Congresos del Centro Médico Nacional.
    • Subject Terms:
      Omeprazole*/adverse effects ; Gastroesophageal Reflux*/drug therapy; Humans ; Rabeprazole
    • Comments:
      Comment on: Gac Med Mex. 2022;158(6):423-429. (PMID: 36657136)
      Comment in: Gac Med Mex. 2023;159(4):366. (PMID: 37699222)
    • Accession Number:
      KG60484QX9 (Omeprazole)
      32828355LL (Rabeprazole)
    • Publication Date:
      Date Created: 20230912 Date Completed: 20230914 Latest Revision: 20231027
    • Publication Date:
      20240829
    • Accession Number:
      10.24875/GMM.M23000798
    • Accession Number:
      37699220